ALAMEDA, Calif., Feb. 25, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company, announced today that two preclinical reports with glial attenuator AV411 (ibudilast) support the pharmacological effect of the drug on enhancing the pain-killing effect of opioids while reducing the addiction properties of commonly used opioids such as morphine and oxycodone. Both studies are published online in Brain Behavior and Immunity.
